Colorectal cancer heterogeneity and targeted therapy: A case for molecular disease subtypes

Cancer Research

Volumn 75, Issue 2, 2015, Pages 245-249

  Linnekamp, Janneke F ^a   Wang, Xin ^b   Medema, Jan Paul ^a   Vermeulen, Louis ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b Harvard Medical School Center for Biomedical Informatics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EGFR PROTEIN, HUMAN;

ARTICLE; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER RESISTANCE; CHROMOSOMAL INSTABILITY; COLORECTAL CANCER; DRUG EFFICACY; GENE EXPRESSION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; HUMAN; INTEGRATIVE MEDICINE; MICROSATELLITE INSTABILITY; MOLECULARLY TARGETED THERAPY; ONCOGENE K RAS; PREDICTION; TUMOR MICROENVIRONMENT; ANTAGONISTS AND INHIBITORS; CLASSIFICATION; COLORECTAL NEOPLASMS; METABOLISM; PATHOLOGY; PERSONALIZED MEDICINE;

COLORECTAL NEOPLASMS; HUMANS; INDIVIDUALIZED MEDICINE; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84920944831     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-2240     Document Type: Article

References (37)

1. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Urol Oncol 2010;11:753-62.
2. De Roock W, De Vriendt V, Normanno N, Ciardiello F, Tejpar S. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Urol Oncol 2011;12: 594-603.
3. Scartozzi M, Bearzi I, Mandolesi A, Giampieri R, Faloppi L, Galizia E, et al. Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients. Br J Cancer 2011;104: 1786-90.
4. De Sousa E, Melo F, Wang X, Jansen M, Fessler E, Trinh A, de Rooij LPMH, et al. Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions. Nat Med 2013;19:614-8.
5. Schlicker A, Beran G, Chresta CM, McWalter G, Pritchard A, Weston S, et al. Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines. BMC Med Genomics 2012;5:66.
6. Perez-Villamil B, Romera-Lopez A, Hernandez-Prieto S, Lopez-Campos G, Calles A, Lopez-Asenjo J-A, et al. Colon cancer molecular subtypes identified by expression profiling and associated to stroma, mucinous type and different clinical behavior. BMC Cancer 2012;12:260.
7. Budinska E, Popovici V, Tejpar S, D'Ario G, Lapique N, Sikora KO, et al. Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer. J Pathol 2013;231:63-76.
8. Roepman P, Schlicker A, Tabernero J, Majewski I, Tian S, Moreno V, et al. Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition. Int J Cancer 2014;134:552-62.
9. Marisa L, de Reynies A, Duval A, Selves J, Gaub MP, Vescovo L, et al. Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value. PLoS Med 2013;10:e1001453.
10. Sadanandam A, Lyssiotis CA, Homicsko K, Collisson EA, Gibb WJ, Wullschleger S, et al. A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med 2013;19:619-25.
11. Walther A, Johnstone E, Swanton C, Midgley R, Tomlinson I, Kerr D. Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer 2009;9:489-99.
12. Malesci A, Laghi L, Bianchi P, Delconte G, Randolph A, Torri V, et al. Reduced likelihood of metastases in patients with microsatellite-unstable colorectal cancer. Clin Cancer Res 2007;13:3831-9.
13. Abulí A, Lozano JJ, Rodríguez-Soler M, Jover R, Bessa X, Muñoz J, et al. Genetic susceptibility variants associated with colorectal cancer prognosis. Carcinogenesis 2013;34:2286-91.
14. TosoliniM, Kirilovsky A, Mlecnik B, Fredriksen T, Mauger S, BindeaG, et al. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res 2011;71:1263-71.
15. IidaN,Dzutsev A, Stewart CA, Smith L, Bouladoux N, Weingarten RA, et al. Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science 2013;342:967-70.
16. Jawad N, Direkze N, Leedham SJ. Inflammatory bowel disease and colon cancer. Recent Results Cancer Res 2011;185:99-115.
17. Lim E, Vaillant F,Wu D, Forrest NC, Pal B, Hart AH, et al. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med 2009;15:907-13.
18. Visvader JE. Cells of origin in cancer. Nature 2011;469:314-22.
19. Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003;349:247-57.
20. Tian S, Simon I, Moreno V, Roepman P, Tabernero J, Snel M, et al. A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction. Gut 2013;62:540-9.
21. Montagut C, Dalmases A, Bellosillo B, Crespo M, Pairet S, Iglesias M, et al. Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer. Nat Med 2012;18:221-3.
22. Luraghi P, Reato G, Cipriano E, Sassi F, Orzan F, Bigatto V, et al. MET signaling in colon cancer stem-like cells blunts the therapeutic response to EGFR inhibitors. Cancer Res 2014;74:1857-69.
23. Takahashi N, Yamada Y, Furuta K, Honma Y, Iwasa S, Takashima A, et al. Serum levels of hepatocyte growth factor and epiregulin are associated with the prognosis on anti-EGFR antibody treatment in KRAS wild-type metastatic colorectal cancer. Br J Cancer 2014;110:2716-27.
24. Scartozzi M,Mandolesi A, Giampieri R, Pierantoni C, Loupakis F, Zaniboni A, et al. Insulin-like growth factor 1 expression correlates with clinical outcome in K-RAS wild type colorectal cancer patients treated with cetuximab and irinotecan. Int J Cancer 2010;1947:1941-7.
25. Yonesaka K, Zejnullahu K, Okamoto I, Satoh T, Takeda M, Fujisaka Y, et al. Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci Transl Med 2011;3:99ra86.
26. Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012;483:100-3.
27. Wang X, Markowetz F, De Sousa E, Melo F, Medema JP, Vermeulen L. Dissecting cancer heterogeneity-an unsupervised classification approach. Int J Biochem Cell Biol 2013;45:2574-9.
28. Sadanandam A, Wang X, Melo FDSE, Gray JW, Vermeulen L, Hanahan D, et al. Reconciliation of classification systems defining molecular subtypes of colorectal cancer -Interrelationships and clinical implications.Cell Cycle 2014;13:353-7.
29. Curtis C, Shah SP, Chin S-F, Turashvili G, Rueda OM, Dunning MJ, et al. The genomic and transcriptomic architecture of 2,000 breast tumors reveals novel subgroups. Nature 2012;486:346-52.
30. Chen H, Xu J, Hong J, Tang R, Zhang X, Fang J-Y. Long noncoding RNA profiles identify five distinct molecular subtypes of colorectal cancer with clinical relevance. Mol Oncol 2014;1-11.
31. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, et al. Efficacy and safety of trastuzumab as a single agent in. J Clin Oncol 2002;20:719-26.
32. Paik S, Kim C, Wolmark N. HER2 status and benefit from adjuvant trastuzumab in breast cancer. N Engl J Med 2008;358:1409-11. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18367751
33. Nahta R, Yu D, Hung M-C, Hortobagyi GN, Esteva FJ. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 2006;3:269-80.
34. Ithimakin S, Day KC, Malik F, Zen Q, Dawsey SJ, Bersano-Begey TF, et al. HER2 drives luminal breast cancer stem cells in the absence of HER2 amplification: implications for efficacy of adjuvant trastuzumab. Cancer Res 2013;73:1635-46.
35. Creighton CJ. Widespread molecular patterns associated with drug sensitivity in breast cancer cell lines, with implications for human tumors. PLoS ONE 2013;8:e71158.
36. Collisson E a, Sadanandam A, Olson P, Gibb WJ, Truitt M, Gu S, et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med 2011;17:500-3.
37. The cancer genome atlas. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012;487:330-7.